1 minute read

MBHB Partner Kevin Noonan Quoted in Article Regarding the FDA's Approach to Naming Requirements for Biosimilars

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin E. Noonan is quoted in a June 5, 2012 edition of in an article entitled, “For Biosimilars, Profit’s All In A Name.” The article focuses on the question of whether the U.S. Food and Drug Administration considers making biosimilars take names different from their brand-name counterparts. Some experts believe the decision will have a big impact on the bottom lines of generics makers, brand-name drug companies and insurers.
View the article